The Department of Health and Human Services this week in a strongly worded letter to Eli Lilly calls into question recent actions by the drug manufacturer to limit 340B hospital and community clinics’ use of 340B contract pharmacy arrangements. The HHS letter is in response to the drug manufacturer’s request for a pre-advisory enforcement action. 

The letter notes that the Health Resources and Services Administration has already directly expressed significant concerns regarding the drug manufacturer’s new policy and is continuing its review.

The HHS letter states that “Lilly cannot and should not view the absence of any questions from the government as somehow endorsing Lilly’s policy especially when this Department is leading government’s response to the COVID-19 pandemic.” 

In addition, HHS warns Eli Lilly that potential litigation is possible if the drug manufacturer “knowingly violates a material condition of the program that results in over-charges to grantees and contractors.”  

Related News Articles

Headline
The full U.S. Court of Appeals for the District of Columbia Circuit Oct. 16 denied AHA’s request to reconsider two decisions from this summer that upheld the…
Headline
The AHA today submitted comments on the Centers for Medicare & Medicaid Services’ outpatient prospective payment system and ambulatory surgical center…
Headline
The AHA again expressed concern to the Department of Health and Human Services about recent actions taken by several major drug manufacturers to limit the…
Headline
The AHA and other national health care groups yesterday urged the Department of Health and Human Services to protect 340B hospitals and the vulnerable…
Headline
The AHA today sent letters to the heads of U.S. operations for five large drug companies — Merck, Eli Lilly, Sanofi, Novartis and AstraZeneca — expressing “…
Headline
The U.S. Court of Appeals for the District of Columbia Circuit today overturned a 2018 district court decision that found the Department of Health and Human…